Welcome to our dedicated page for SureNano Science news (Ticker: SURNF), a resource for investors and traders seeking the latest updates and insights on SureNano Science stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SureNano Science's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SureNano Science's position in the market.
SureNano Science (OTCQB:SURNF) has announced a recapitalization plan consisting of two key components: a $85,000 debt settlement with insider Charles Malette and a private placement to raise up to $215,000. Both transactions will issue shares at $0.10 per share, totaling up to 3,000,000 shares.
The company also reported results from its August 8, 2025 annual general and special meeting, where 70.29% of shareholders participated. All proposed directors were unanimously elected, Buckley Dodds CPA was appointed as auditor, and the long-term incentive plan was approved. Upon completion of the debt settlement, director Charles Malette will own 34.8% of common shares.
FAQ
What is the market cap of SureNano Science (SURNF)?
